Homocysteine metabolism in polycystic ovary syndrome

Gynecological Endocrinology

Volumn 28, Issue 3, 2012, Pages 186-189

  Grodnitskaya, Elena E ^a   Kurtser, Mark A ^a  

^a Moscow Centre of Family Planning and Reproduction   (Russian Federation)

Author keywords

Endothelial dysfunction; Folate; Homocysteine; Insulin resistance; Methylenetetrahydrofolate reductase; Polycystic ovary syndrome

Indexed keywords

ATORVASTATIN; DROSPIRENONE; HOMOCYSTEINE; METFORMIN; ORAL CONTRACEPTIVE AGENT; ROSIGLITAZONE; SIMVASTATIN;

ARTICLE; CONCENTRATION (PARAMETERS); DRUG ACTIVITY; HUMAN; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERANDROGENISM; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 84856946157     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.589927     Document Type: Article

References (48)

1. Orio F Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, Labella D, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:673-679. (Pubitemid 36207807)
2. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
3. Forges T, Monnier-Barbarino P, Alberto JM, Guéant-Rodriguez RM, Daval JL, Guéant JL. Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update 2007;13:225-238. (Pubitemid 47064259)
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288(16):2015-2022.
5. Framingham Ofspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham ofspring study. Diabetes Care 2001;24(8):1403-1410.
6. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12(5):483-497.
7. Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA, Tucker MJ. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001;27:163-168. (Pubitemid 32743245)
8. Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, de Aloysio D. Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril 2009;91:2537-2544. Posted online on November 25, 2010.
9. Bagos PG. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. Mol Hum Reprod 2009;15:19-26.
10. Badawy A, State O, El Gawad SSh, El Aziz OA. Plasma homocysteine and polycystic ovary syndrome: the missed link. Eur J Obstet Gynecol Reprod Biol 2007;131:68-72. (Pubitemid 46283206)
11. Bayraktar F, Dereli D, Ozgen AG, Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004;51:601-608. (Pubitemid 40214363)
12. Carlsen SM, Kjøtrød S, Vanky E, Romundstad P. Homocysteine levels are unafected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2007;86:145-150.
13. Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic infammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:505-510. (Pubitemid 47628538)
14. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:721-727. (Pubitemid 36426948)
15. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sherif R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004;60:560-567. (Pubitemid 38669845)
16. Yilmaz N, Pektas M, Tonguc E, Kilic S, Gulerman C, Gungor T, Mollamahmutoglu L. The correlation of plasma homocysteine with insulin resistance in polycystic ovary syndrome. J Obstet Gynaecol Res 2008;34:384-391. (Pubitemid 351832328)
17. Kilic-Okman T, Guldiken S, Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. Endocr J 2004;51:505-508. (Pubitemid 39536360)
18. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53:157-162. (Pubitemid 34621637)
19. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M. The efects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005;20:3333-3340. (Pubitemid 41742509)
20. Kazerooni T, Asadi N, Dehbashi S, Zolghadri J. Efect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome. Int J Gynaecol Obstet 2008;101:156-160.
21. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND. Efects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complicat 2007;21:118-123.
22. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005;20:894-899. (Pubitemid 40667831)
23. Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, Matíes M, Escobar-Morreale HF. Efects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: infuence of obesity and smoking. Eur J Endocrinol 2009;160:469-480.
24. Vrbíková J, Bicíková M, Tallová J, Hill M, Stárka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002;110:74-76. (Pubitemid 34296855)
25. Wulfelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Efects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003;254:455-463. (Pubitemid 37346629)
26. Kilicdag EB, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, Haydardedeoglu B, Kuscu E. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 2005;20:1521-1528. (Pubitemid 40852242)
27. Palomba S, Falbo A, Giallauria F, Russo T, Tolino A, Zullo F, Colao A, Orio F. Efects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010;33:246-251.
28. Kilic S, Yilmaz N, Zulfkaroglu E, Erdogan G, Aydin M, Batioglu S. Infammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecol Endocrinol 2010 [Epub ahead of print]
29. Henning BF, Tepel M, Riezler R, Gillessen A, Doberauer C. Vitamin supplementation during weight reduction-favourable efect on homocysteine metabolism. Res Exp Med (Berl) 1998;198:37-42. (Pubitemid 28376863)
30. Kucuk M, Kilic-Okman T. Hormone profles and clinical outcome afer laparoscopic ovarian drilling in women with polycystic ovary syndrome. Med Sci Monit 2005;11:CR29-CR34. (Pubitemid 40116397)
31. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse EW, Prelevic GM. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4496-4501. (Pubitemid 35247032)
32. Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G. Comparative efects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009;92:635-642.
33. Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception 2006;73:348-351. (Pubitemid 43375092)
34. Gul OB, Somunkiran A, Yucel O, Demirci F, Ozdemir I. The efect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet 2008;277:25-30. (Pubitemid 350160064)
35. Mancini F, Cianciosi A, Persico N, Facchinetti F, Busacchi P, Battaglia C. Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 2010;202:169. e1-169.e8.
36. Makedos A, Goulis DG, Papanikolaou A, Panidis D. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study. Angiology 2010;61:595-601.
37. Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011;68:13-16.
38. Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witteman JC, Stehouwer CD. Increased plasma homocysteine afer menopause. Atherosclerosis 2000;149:163-168. (Pubitemid 30125985)
39. van Baal WM, Smolders RG, van der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485-491. (Pubitemid 29460927)
40. Yarali H, Yildirir A, Aybar F, Kabakçi G, Bükülmez O, Akgül E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-516.
41. Morgante G, La Marca A, Setacci F, Setacci C, Petraglia F, De Leo V. The cardiovascular risk factor homocysteine is not elevated in young women with hyperandrogenism or hypoestrogenism. Gynecol Obstet Invest 2002;53:200-203. (Pubitemid 34977919)
42. Arikan S, Bahceci M, Tuzcu A, Kale E, Gökalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol 2010;26:161-166.
43. Moini A, Sarrafon F, Ziaei S, Faghihzadeh S, Arabipoor A. A possible role for familial thrombophilia in women with polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:80-85.
44. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women infuences the fndings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-2549. (Pubitemid 40686289)
45. de la Calle M, Gallardo T, Diestro MD, Hernanz A, Pérez E, Fernández-Miranda C. Increased homocysteine levels in polycystic ovary syndrome. Med Clin (Barc). 2007;129(8):292-294. (Pubitemid 47574116)
46. Mohamadin AM, Habib FA, Al-Saggaf AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. Ann Saudi Med 2010;30:278-283.
47. Karaer A, Cavkaytar S, Mert I, Buyukkagnici U, Batioglu S. Cardiovascular risk factors in polycystic ovary syndrome. J Obstet Gynaecol 2010;30:387-392.
48. Pamuk BO, Torun AN, Kulaksizoglu M, Ertugrul D, Cifci O, Kulaksizoglu S, Yildirim E, Demirag NG. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril 2010;93:1227-1233.